Higher antipsychotic exposure related to poorer cognition in midlife schizophrenia. Potential biases related to this naturalistic design may contribute to the effects. Higher antipsychotic doses may negatively affect cognitive course in schizophrenia. Preventing or attenuating cognitive recovery may be an explanation for the results.